SCHEMBL448460

SCHEMBL448460

CC1(C)NS(=O)(=O)c2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.39
MEN1 O00255 2/20 0.39
NOX1 Q9Y5S8 1/20 0.39
CA12 O43570 5/20 0.38
CA1 P00915 5/20 0.38
CA2 P00918 5/20 0.38
CA9 Q16790 5/20 0.38
CA4 P22748 4/20 0.38
CA7 P43166 4/20 0.38
KDM4E B2RXH2 3/20 0.35
LMNA P02545 2/20 0.35
PDK2 Q15119 1/20 0.35
PDK4 Q16654 1/20 0.35
USP2 O75604 1/20 0.35
BCHE P06276 1/20 0.35
CA6 P23280 1/20 0.35
CA5A P35218 1/20 0.35
CA14 Q9ULX7 1/20 0.35
CA5B Q9Y2D0 1/20 0.35
GPR3 P46089 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL446104 0.98 KMT2A (0.38) KMT2AMEN1NOX1CA12CA1
SCHEMBL5523699 0.75 KMT2A (0.39) KMT2AMEN1NOX1CA12CA1
SCHEMBL17169742 0.75 KMT2A (0.39) KMT2AMEN1NOX1CA12CA1
SCHEMBL26048255 0.75 KMT2A (0.39) KMT2AMEN1NOX1CA12CA1
SCHEMBL14425421 0.75 CA1 (0.41) KMT2AMEN1CA12CA1CA2
SCHEMBL7685977 0.75 KMT2A (0.35) KMT2AMEN1NOX1CA12CA1
SCHEMBL428285 0.75 CA1 (0.45) CA12CA1CA2CA9CA4
SCHEMBL21910775 0.75 CA9 (0.48) KMT2AMEN1NOX1CA12CA1
SCHEMBL26705045 0.73 ALDH1A1 (0.38) KMT2AMEN1LMNAALDH1A1CYP1A2
SCHEMBL24697302 0.73 CA2 (0.44) CA12CA1CA2CA9CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078091-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC (US) 2026-03-19 US disclosed
US-20240300892-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC (US) 2024-09-12 US disclosed
US-20230350294-A1 Negative Photosensitive Resin Composition, Patterning Process, Interlayer Insulating Film, Surface Protection Film, And Electronic Component SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-11-02 US disclosed
EP-3483143-B1 PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC (US) 2023-10-18 EP disclosed
US-11768434-B2 Polymer having a structure of polyamide, polyamide-imide, or polyimide, photosensitive resin composition, patterning process, photosensitive dry film, and protective film for electric and electronic parts SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-09-26 US disclosed
US-11768434-B2 Polymer having a structure of polyamide, polyamide-imide, or polyimide, photosensitive resin composition, patterning process, photosensitive dry film, and protective film for electric and electronic parts SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-09-26 US disclosed
US-20230242495-A1 Nitrosation Reagents and Methods THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-08-03 US disclosed
US-20230242495-A1 Nitrosation Reagents and Methods THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-08-03 US disclosed
EP-4092012-A1 PIPERIDINONE DERIVATIVES AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2022-11-23 EP disclosed
US-20220169611-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer AMGEN INC (US) 2022-06-02 US disclosed
US-20030195230-A1 Substituted amine derivatives and methods of use AMGEN INC. 2003-10-16 US disclosed
US-20030134836-A1 Substituted arylamine derivatives and methods of use AMGEN INC. 2003-07-17 US disclosed
US-20030125339-A1 Substituted alkylamine derivatives and methods of use AMGEN INC. 2003-07-03 US disclosed
US-20020147198-A1 Substituted arylamine derivatives and methods of use AMGEN INC. 2002-10-10 US disclosed
US-6346622-B1 ENANTIOMORPHS AND ISOMERS ABBOTT LABORATORIES 2002-02-12 US disclosed
US-6300354-B1 FOR THERAPY OF NEUROLEPTIC DISEASES BASF AKTIENGESELLSCHAFT (DE) 2001-10-09 US disclosed
CN-1312809-A N-substituted azabicycloheptane deriratives, production and use thereof BASF AG (DE) 2001-09-12 CN disclosed
US-6191297-B1 HYDROSILATION OF FUNCTIONALLIZED ALLYL COMPOUNDS, E.G. ALLYL CHLORIDE, BY HYDROGEN SILANES, E.G. DICHLOROMETHYLSILANE, USING A CATALYST OF A COMPLEX OF PLATINUM AND ONE OR MORE SULFUR-CONTAINING LIGANDS; EFFICIENCY DEGUSSA-HULS AG (DE) 2001-02-20 US disclosed
CN-1277607-A 2-substituted 1,2-benzisothiazole derivatives and their use as serotonin antagonists (5-HT1A, 5-HT1b and 5-HT1D) BASF AG (DE) 2000-12-20 CN disclosed
CN-1241570-A New process for preparation of organosilanes functionalised in the 3-position DEGUSSA (DE) 2000-01-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300892-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer MDM2, TP53, CDKN1A KMT2A 919/4885MEN1 1267/4885NOX1 2258/4885
US-20260078091-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer TP53, HIF1AN, MDM2 KMT2A 1019/4885MEN1 3957/4885NOX1 3797/4885
US-20030125339-A1 Substituted alkylamine derivatives and methods of use AADAC, NAT1, PIGO KMT2A 1313/4885MEN1 1464/4885NOX1 420/4885
US-20220169611-A1 Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer MDM2, TP53, CDKN1A KMT2A 919/4885MEN1 1267/4885NOX1 2258/4885
US-20030134836-A1 Substituted arylamine derivatives and methods of use NAT1, AADAC, AHR KMT2A 1457/4885MEN1 2237/4885NOX1 204/4885
US-20230242495-A1 Nitrosation Reagents and Methods NOS2, NOS1, NNMT KMT2A 3043/4885MEN1 1149/4885NOX1 7/4885
US-20020147198-A1 Substituted arylamine derivatives and methods of use NAT1, AADAC, AHR KMT2A 1457/4885MEN1 2237/4885NOX1 204/4885
US-20030195230-A1 Substituted amine derivatives and methods of use MAOB, HNMT, FLT4 KMT2A 1259/4885MEN1 664/4885NOX1 258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.